Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Depreciation & Amortization history
Currency unavailable · from the cash flow
No Depreciation & Amortization data reported for this period type.
Depreciation & Amortization vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M USD | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $2.43M USD | +1.2% | +1.2% | 1.0% | |
| LTM Jun 2026 | $1.54M USD | -10.7% | -27.6% | 0.5% | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $163K USD | +129.6% | -10.0% | — |
| LTM Mar 2026 | $158K USD | +4.6% | +29.7% | — | |
| LTM Sep 2026 | $0 USD | — | +72.0% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +2.9% | +1.2% | 1.0% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.